HC Wainwright Issues Optimistic Outlook for Balchem Earnings

Balchem Co. (NASDAQ:BCPC) – Research analysts at HC Wainwright boosted their FY2024 earnings estimates for Balchem in a research report issued to clients and investors on Monday, November 4th. HC Wainwright analyst R. Selvaraju now anticipates that the basic materials company will earn $4.01 per share for the year, up from their previous estimate of $3.81. HC Wainwright currently has a “Buy” rating and a $190.00 target price on the stock. The consensus estimate for Balchem’s current full-year earnings is $4.09 per share. HC Wainwright also issued estimates for Balchem’s Q4 2024 earnings at $1.10 EPS, Q1 2025 earnings at $1.06 EPS, Q2 2025 earnings at $1.09 EPS, Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.19 EPS and FY2025 earnings at $4.47 EPS.

Separately, StockNews.com raised Balchem from a “hold” rating to a “buy” rating in a report on Monday, October 28th.

Balchem Trading Down 3.7 %

Balchem stock opened at $176.63 on Wednesday. Balchem has a 52-week low of $116.84 and a 52-week high of $186.03. The company has a quick ratio of 1.90, a current ratio of 2.98 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $5.74 billion, a price-to-earnings ratio of 47.48, a PEG ratio of 5.28 and a beta of 0.65. The firm has a 50-day moving average price of $172.07 and a two-hundred day moving average price of $163.86.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Balchem by 3.8% in the first quarter. Vanguard Group Inc. now owns 3,935,935 shares of the basic materials company’s stock worth $609,873,000 after purchasing an additional 144,423 shares during the period. Victory Capital Management Inc. raised its position in shares of Balchem by 129.7% during the 3rd quarter. Victory Capital Management Inc. now owns 98,853 shares of the basic materials company’s stock worth $17,398,000 after buying an additional 55,822 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Balchem by 32.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 193,146 shares of the basic materials company’s stock worth $29,929,000 after acquiring an additional 47,036 shares during the period. Congress Asset Management Co. boosted its holdings in shares of Balchem by 12.4% in the third quarter. Congress Asset Management Co. now owns 301,440 shares of the basic materials company’s stock valued at $53,053,000 after acquiring an additional 33,373 shares in the last quarter. Finally, Conestoga Capital Advisors LLC increased its stake in shares of Balchem by 2.7% during the second quarter. Conestoga Capital Advisors LLC now owns 1,155,209 shares of the basic materials company’s stock valued at $177,844,000 after acquiring an additional 29,825 shares during the period. Institutional investors own 87.91% of the company’s stock.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.